Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Mar 21;82(8):1371–1380. doi: 10.1054/bjoc.1999.1075

Chemotherapy for high-grade gliomas

E Galanis 1, J Buckner 1
PMCID: PMC2363368  PMID: 10780513

Full Text

The Full Text of this article is available as a PDF (139.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ameri A., Poisson M., Chen Q. M., Delattre J. Y. Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study. J Neurooncol. 1993 Jul;17(1):43–46. doi: 10.1007/BF01054273. [DOI] [PubMed] [Google Scholar]
  2. Barba D., Saris S. C., Holder C., Rosenberg S. A., Oldfield E. H. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg. 1989 Feb;70(2):175–182. doi: 10.3171/jns.1989.70.2.0175. [DOI] [PubMed] [Google Scholar]
  3. Belanich M., Pastor M., Randall T., Guerra D., Kibitel J., Alas L., Li B., Citron M., Wasserman P., White A. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 1996 Feb 15;56(4):783–788. [PubMed] [Google Scholar]
  4. Bischoff J. R., Kirn D. H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J. A., Sampson-Johannes A., Fattaey A. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996 Oct 18;274(5286):373–376. doi: 10.1126/science.274.5286.373. [DOI] [PubMed] [Google Scholar]
  5. Bower M., Newlands E. S., Bleehen N. M., Brada M., Begent R. J., Calvert H., Colquhoun I., Lewis P., Brampton M. H. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol. 1997;40(6):484–488. doi: 10.1007/s002800050691. [DOI] [PubMed] [Google Scholar]
  6. Brada M., Sharpe G. Chemotherapy of high-grade gliomas: beginning of a new era or the end of the old? Eur J Cancer. 1996 Dec;32A(13):2193–2194. doi: 10.1016/s0959-8049(96)00400-5. [DOI] [PubMed] [Google Scholar]
  7. Brady L. W., Miyamoto C., Woo D. V., Rackover M., Emrich J., Bender H., Dadparvar S., Steplewski Z., Koprowski H., Black P. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys. 1992;22(1):225–230. doi: 10.1016/0360-3016(92)91009-c. [DOI] [PubMed] [Google Scholar]
  8. Brem H., Piantadosi S., Burger P. C., Walker M., Selker R., Vick N. A., Black K., Sisti M., Brem S., Mohr G. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995 Apr 22;345(8956):1008–1012. doi: 10.1016/s0140-6736(95)90755-6. [DOI] [PubMed] [Google Scholar]
  9. Buckner J. C., Brown L. D., Cascino T. L., Gerstner J. B., Krook J. E., Westberg M. W., Wiesenfeld M., O'Fallon J. R., Scheithauer B. Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma. J Neurooncol. 1990 Dec;9(3):249–254. [PubMed] [Google Scholar]
  10. Burger P. C., Vogel F. S., Green S. B., Strike T. A. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer. 1985 Sep 1;56(5):1106–1111. doi: 10.1002/1097-0142(19850901)56:5<1106::aid-cncr2820560525>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  11. Cairncross G., Macdonald D., Ludwin S., Lee D., Cascino T., Buckner J., Fulton D., Dropcho E., Stewart D., Schold C., Jr Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994 Oct;12(10):2013–2021. doi: 10.1200/JCO.1994.12.10.2013. [DOI] [PubMed] [Google Scholar]
  12. Cairncross J. G., Macdonald D. R. Chemotherapy for oligodendroglioma. Progress report. Arch Neurol. 1991 Feb;48(2):225–227. doi: 10.1001/archneur.1991.00530140123026. [DOI] [PubMed] [Google Scholar]
  13. Cairncross J. G., Macdonald D. R., Ramsay D. A. Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery. 1992 Jul;31(1):78–82. doi: 10.1227/00006123-199207000-00011. [DOI] [PubMed] [Google Scholar]
  14. Cascino T. L., Brown L. D., Morton R. F., Everson L. K., Marschke R. F., Dinapoli R. P., O'Fallon J. R. Evaluation of fludarabine phosphate in patients with recurrent glioma. Am J Clin Oncol. 1988 Oct;11(5):586–588. doi: 10.1097/00000421-198810000-00015. [DOI] [PubMed] [Google Scholar]
  15. Chamberlain M. C., Kormanik P. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol. 1995 Aug;13(8):2066–2071. doi: 10.1200/JCO.1995.13.8.2066. [DOI] [PubMed] [Google Scholar]
  16. Chamberlain M. C., Prados M. D., Silver P., Levin V. A. A phase II trial of oral melphalan in recurrent primary brain tumors. Am J Clin Oncol. 1988 Feb;11(1):52–54. doi: 10.1097/00000421-198802000-00011. [DOI] [PubMed] [Google Scholar]
  17. Chang C. H., Horton J., Schoenfeld D., Salazer O., Perez-Tamayo R., Kramer S., Weinstein A., Nelson J. S., Tsukada Y. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer. 1983 Sep 15;52(6):997–1007. doi: 10.1002/1097-0142(19830915)52:6<997::aid-cncr2820520612>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  18. Chang S. M., Kuhn J. G., Rizzo J., Robins H. I., Schold S. C., Jr, Spence A. M., Berger M. S., Mehta M. P., Bozik M. E., Pollack I. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol. 1998 Jun;16(6):2188–2194. doi: 10.1200/JCO.1998.16.6.2188. [DOI] [PubMed] [Google Scholar]
  19. Cohadon F., Aouad N., Rougier A., Vital C., Rivel J., Dartigues J. F. Histologic and non-histologic factors correlated with survival time in supratentorial astrocytic tumors. J Neurooncol. 1985;3(2):105–111. doi: 10.1007/BF02228885. [DOI] [PubMed] [Google Scholar]
  20. Coyle T., Baptista J., Winfield J., Clark K., Poiesz B., Kirshner J., Scalzo A., Newman-Palmer N., King R., Graziano S. Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study. J Clin Oncol. 1990 Dec;8(12):2014–2018. doi: 10.1200/JCO.1990.8.12.2014. [DOI] [PubMed] [Google Scholar]
  21. D'Amato R. J., Loughnan M. S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082–4085. doi: 10.1073/pnas.91.9.4082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Daumas-Duport C., Scheithauer B., O'Fallon J., Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer. 1988 Nov 15;62(10):2152–2165. doi: 10.1002/1097-0142(19881115)62:10<2152::aid-cncr2820621015>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  23. Deutsch M., Green S. B., Strike T. A., Burger P. C., Robertson J. T., Selker R. G., Shapiro W. R., Mealey J., Jr, Ransohoff J., 2nd, Paoletti P. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1389–1396. doi: 10.1016/0360-3016(89)90939-5. [DOI] [PubMed] [Google Scholar]
  24. Dietrich P. Y., Walker P. R., Saas P., de Tribolet N. Immunobiology of gliomas: new perspectives for therapy. Ann N Y Acad Sci. 1997 Sep 17;824:124–140. doi: 10.1111/j.1749-6632.1997.tb46215.x. [DOI] [PubMed] [Google Scholar]
  25. Dinapoli R. P., Brown L. D., Arusell R. M., Earle J. D., O'Fallon J. R., Buckner J. C., Scheithauer B. W., Krook J. E., Tschetter L. K., Maier J. A. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol. 1993 Jul;11(7):1316–1321. doi: 10.1200/JCO.1993.11.7.1316. [DOI] [PubMed] [Google Scholar]
  26. Dolan M. E., Pegg A. E. O6-benzylguanine and its role in chemotherapy. Clin Cancer Res. 1997 Jun;3(6):837–847. [PubMed] [Google Scholar]
  27. Elliott T. E., Buckner J. C., Cascino T. L., Levitt R., O'Fallon J. R., Scheithauer B. W. Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma. J Neurooncol. 1991 Feb;10(1):27–30. doi: 10.1007/BF00151244. [DOI] [PubMed] [Google Scholar]
  28. Elliott T. E., Dinapoli R. P., O'Fallon J. R., Krook J. E., Earle J. D., Morton R. F., Levitt R., Tschetter L. K., Scheithauer B. W., Pfeifle D. M. Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma. J Neurooncol. 1997 Jul;33(3):239–250. doi: 10.1023/a:1005735405986. [DOI] [PubMed] [Google Scholar]
  29. Eyre H. J., Quagliana J. M., Eltringham J. R., Frank J., O'Bryan R. M., McDonald B., Rivkin S. E. Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group Report. J Neurooncol. 1983;1(3):171–177. doi: 10.1007/BF00165600. [DOI] [PubMed] [Google Scholar]
  30. Fine H. A., Antman K. H. High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience. Bone Marrow Transplant. 1992 Oct;10(4):315–321. [PubMed] [Google Scholar]
  31. Fine H. A., Dear K. B., Loeffler J. S., Black P. M., Canellos G. P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993 Apr 15;71(8):2585–2597. doi: 10.1002/1097-0142(19930415)71:8<2585::aid-cncr2820710825>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  32. Fine H. A., Figg W. D., Jaeckle K., Wen P. Y., Kyritsis A. P., Loeffler J. S., Levin V. A., Black P. M., Kaplan R., Pluda J. M. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000 Feb;18(4):708–715. doi: 10.1200/JCO.2000.18.4.708. [DOI] [PubMed] [Google Scholar]
  33. Folkman J., Klagsbrun M. Angiogenic factors. Science. 1987 Jan 23;235(4787):442–447. doi: 10.1126/science.2432664. [DOI] [PubMed] [Google Scholar]
  34. Ford J., Osborn C., Barton T., Bleehen N. M. A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur J Cancer. 1998 Oct;34(11):1807–1811. doi: 10.1016/s0959-8049(98)00155-5. [DOI] [PubMed] [Google Scholar]
  35. Friedman H. S., Petros W. P., Friedman A. H., Schaaf L. J., Kerby T., Lawyer J., Parry M., Houghton P. J., Lovell S., Rasheed K. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999 May;17(5):1516–1525. doi: 10.1200/JCO.1999.17.5.1516. [DOI] [PubMed] [Google Scholar]
  36. Fulling K. H., Garcia D. M. Anaplastic astrocytoma of the adult cerebrum. Prognostic value of histologic features. Cancer. 1985 Mar 1;55(5):928–931. doi: 10.1002/1097-0142(19850301)55:5<928::aid-cncr2820550503>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  37. Galanis E., Buckner J. C., Schomberg P. J., Hammack J. E., Raffel C., Scheithauer B. W. Effective chemotherapy for advanced CNS embryonal tumors in adults. J Clin Oncol. 1997 Aug;15(8):2939–2944. doi: 10.1200/JCO.1997.15.8.2939. [DOI] [PubMed] [Google Scholar]
  38. Giannone L., Wolff S. N. Phase II treatment of central nervous system gliomas with high-dose etoposide and autologous bone marrow transplantation. Cancer Treat Rep. 1987 Jul-Aug;71(7-8):759–761. [PubMed] [Google Scholar]
  39. Glass J., Hochberg F. H., Gruber M. L., Louis D. N., Smith D., Rattner B. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg. 1992 May;76(5):741–745. doi: 10.3171/jns.1992.76.5.0741. [DOI] [PubMed] [Google Scholar]
  40. Grant R., Slattery J., Gregor A., Whittle I. R. Recording neurological impairment in clinical trials of glioma. J Neurooncol. 1994;19(1):37–49. doi: 10.1007/BF01051047. [DOI] [PubMed] [Google Scholar]
  41. Green S. B., Byar D. P., Walker M. D., Pistenmaa D. A., Alexander E., Jr, Batzdorf U., Brooks W. H., Hunt W. E., Mealey J., Jr, Odom G. L. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep. 1983 Feb;67(2):121–132. [PubMed] [Google Scholar]
  42. Grossman S. A., Hochberg F., Fisher J., Chen T. L., Kim L., Gregory R., Grochow L. B., Piantadosi S. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother Pharmacol. 1998;42(2):118–126. doi: 10.1007/s002800050794. [DOI] [PubMed] [Google Scholar]
  43. Grossman S. A., Wharam M., Sheidler V., Kleinberg L., Zeltzman M., Yue N., Piantadosi S. Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol. 1997 Jul;15(7):2596–2603. doi: 10.1200/JCO.1997.15.7.2596. [DOI] [PubMed] [Google Scholar]
  44. Gutin P. H., Wilson C. B., Kumar A. R., Boldrey E. B., Levin V., Powell M., Enot K. J. Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer. 1975 May;35(5):1398–1404. doi: 10.1002/1097-0142(197505)35:5<1398::aid-cncr2820350524>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  45. Hoogstraten B., Gottlieb J. A., Caoili E., Tucker W. G., Talley R. W., Haut A. CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer. Phase II study. Cancer. 1973 Jul;32(1):38–43. doi: 10.1002/1097-0142(197307)32:1<38::aid-cncr2820320105>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  46. Jeremic B., Grujicic D., Jevremovic S., Stanisavljevic B., Milojevic L., Djuric L., Mijatovic L. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol. 1992 Jul;10(7):1074–1077. doi: 10.1200/JCO.1992.10.7.1074. [DOI] [PubMed] [Google Scholar]
  47. Kessinger A., Lemon H. M., Foley J. F. VM-26 as a second drug in the treatment of brain gliomas. Cancer Treat Rep. 1979 Mar;63(3):511–512. [PubMed] [Google Scholar]
  48. Kohl N. E., Mosser S. D., deSolms S. J., Giuliani E. A., Pompliano D. L., Graham S. L., Smith R. L., Scolnick E. M., Oliff A., Gibbs J. B. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science. 1993 Jun 25;260(5116):1934–1937. doi: 10.1126/science.8316833. [DOI] [PubMed] [Google Scholar]
  49. Kyritsis A. P., Yung W. K., Bruner J., Gleason M. J., Levin V. A. The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery. 1993 Mar;32(3):365–371. doi: 10.1227/00006123-199303000-00005. [DOI] [PubMed] [Google Scholar]
  50. LUSE S. A. Electron microscopic studies of brain tumors. Neurology. 1960 Oct;10:881–905. doi: 10.1212/wnl.10.10.881. [DOI] [PubMed] [Google Scholar]
  51. Lampert K., Machein U., Machein M. R., Conca W., Peter H. H., Volk B. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol. 1998 Aug;153(2):429–437. doi: 10.1016/S0002-9440(10)65586-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Lesser G. J., Grossman S. The chemotherapy of high-grade astrocytomas. Semin Oncol. 1994 Apr;21(2):220–235. [PubMed] [Google Scholar]
  53. Levin V. A., Edwards M. S., Wright D. C., Seager M. L., Schimberg T. P., Townsend J. J., Wilson C. B. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep. 1980 Feb-Mar;64(2-3):237–244. [PubMed] [Google Scholar]
  54. Levin V. A., Silver P., Hannigan J., Wara W. M., Gutin P. H., Davis R. L., Wilson C. B. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321–324. doi: 10.1016/0360-3016(90)90096-3. [DOI] [PubMed] [Google Scholar]
  55. Li V. W., Folkerth R. D., Watanabe H., Yu C., Rupnick M., Barnes P., Scott R. M., Black P. M., Sallan S. E., Folkman J. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet. 1994 Jul 9;344(8915):82–86. doi: 10.1016/s0140-6736(94)91280-7. [DOI] [PubMed] [Google Scholar]
  56. Macdonald D. R., Gaspar L. E., Cairncross J. G. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol. 1990 May;27(5):573–574. doi: 10.1002/ana.410270519. [DOI] [PubMed] [Google Scholar]
  57. Mak M., Fung L., Strasser J. F., Saltzman W. M. Distribution of drugs following controlled delivery to the brain interstitium. J Neurooncol. 1995 Nov;26(2):91–102. doi: 10.1007/BF01060215. [DOI] [PubMed] [Google Scholar]
  58. Mineta T., Rabkin S. D., Yazaki T., Hunter W. D., Martuza R. L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995 Sep;1(9):938–943. doi: 10.1038/nm0995-938. [DOI] [PubMed] [Google Scholar]
  59. Mortimer J. E., Crowley J., Eyre H., Weiden P., Eltringham J., Stuckey W. J. A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors. A Southwest Oncology Group study. Cancer. 1992 Mar 1;69(5):1220–1223. doi: 10.1002/cncr.2820690525. [DOI] [PubMed] [Google Scholar]
  60. Narla R. K., Liu X. P., Klis D., Uckun F. M. Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154). Clin Cancer Res. 1998 Oct;4(10):2463–2471. [PubMed] [Google Scholar]
  61. Nelson D. F., Diener-West M., Horton J., Chang C. H., Schoenfeld D., Nelson J. S. Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr. 1988;(6):279–284. [PubMed] [Google Scholar]
  62. Nelson D. F., Diener-West M., Weinstein A. S., Schoenfeld D., Nelson J. S., Sause W. T., Chang C. H., Goodman R., Carabell S. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. Int J Radiat Oncol Biol Phys. 1986 Oct;12(10):1793–1800. doi: 10.1016/0360-3016(86)90321-4. [DOI] [PubMed] [Google Scholar]
  63. Newlands E. S., Blackledge G. R., Slack J. A., Rustin G. J., Smith D. B., Stuart N. S., Quarterman C. P., Hoffman R., Stevens M. F., Brampton M. H. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992 Feb;65(2):287–291. doi: 10.1038/bjc.1992.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Newlands E. S., O'Reilly S. M., Glaser M. G., Bower M., Evans H., Brock C., Brampton M. H., Colquhoun I., Lewis P., Rice-Edwards J. M. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer. 1996 Dec;32A(13):2236–2241. doi: 10.1016/s0959-8049(96)00258-4. [DOI] [PubMed] [Google Scholar]
  65. Newlands E. S., Stevens M. F., Wedge S. R., Wheelhouse R. T., Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997 Jan;23(1):35–61. doi: 10.1016/s0305-7372(97)90019-0. [DOI] [PubMed] [Google Scholar]
  66. O'Reilly M. S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. S., Flynn E., Birkhead J. R., Olsen B. R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997 Jan 24;88(2):277–285. doi: 10.1016/s0092-8674(00)81848-6. [DOI] [PubMed] [Google Scholar]
  67. Oldfield E. H., Ram Z., Culver K. W., Blaese R. M., DeVroom H. L., Anderson W. F. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther. 1993 Feb;4(1):39–69. doi: 10.1089/hum.1993.4.1-39. [DOI] [PubMed] [Google Scholar]
  68. Osoba D., Aaronson N. K., Muller M., Sneeuw K., Hsu M. A., Yung W. K., Brada M., Newlands E. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res. 1996 Feb;5(1):139–150. doi: 10.1007/BF00435979. [DOI] [PubMed] [Google Scholar]
  69. Phillips G. L., Wolff S. N., Fay J. W., Herzig R. H., Lazarus H. M., Schold C., Herzig G. P. Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. J Clin Oncol. 1986 May;4(5):639–645. doi: 10.1200/JCO.1986.4.5.639. [DOI] [PubMed] [Google Scholar]
  70. Plate K. H., Breier G., Weich H. A., Mennel H. D., Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer. 1994 Nov 15;59(4):520–529. doi: 10.1002/ijc.2910590415. [DOI] [PubMed] [Google Scholar]
  71. Rodriguez L. A., Prados M., Silver P., Levin V. A. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer. 1989 Dec 15;64(12):2420–2423. doi: 10.1002/1097-0142(19891215)64:12<2420::aid-cncr2820641204>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  72. Sanson M., Ameri A., Monjour A., Sahmoud T., Ronchin P., Poisson M., Delattre J. Y. Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. Eur J Cancer. 1996 Dec;32A(13):2229–2235. doi: 10.1016/s0959-8049(96)00299-7. [DOI] [PubMed] [Google Scholar]
  73. Sebag-Montefiore D. J., Douek E., Kingston J. E., Plowman P. N. Intracranial germ cell tumours: I. Experience with platinum based chemotherapy and implications for curative chemoradiotherapy. Clin Oncol (R Coll Radiol) 1992 Nov;4(6):345–350. doi: 10.1016/s0936-6555(05)81122-7. [DOI] [PubMed] [Google Scholar]
  74. Shapiro W. R., Green S. B., Burger P. C., Mahaley M. S., Jr, Selker R. G., VanGilder J. C., Robertson J. T., Ransohoff J., Mealey J., Jr, Strike T. A. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg. 1989 Jul;71(1):1–9. doi: 10.3171/jns.1989.71.1.0001. [DOI] [PubMed] [Google Scholar]
  75. Shapiro W. R., Green S. B., Burger P. C., Selker R. G., VanGilder J. C., Robertson J. T., Mealey J., Jr, Ransohff J., Mahaley M. S., Jr A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg. 1992 May;76(5):772–781. doi: 10.3171/jns.1992.76.5.0772. [DOI] [PubMed] [Google Scholar]
  76. Spence A. M., Berger M. S., Livingston R. B., Ali-Osman F., Griffin B. Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. J Neurooncol. 1992 Feb;12(2):187–191. doi: 10.1007/BF00172671. [DOI] [PubMed] [Google Scholar]
  77. Takamiya Y., Brem H., Ojeifo J., Mineta T., Martuza R. L. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery. 1994 May;34(5):869–875. doi: 10.1227/00006123-199405000-00013. [DOI] [PubMed] [Google Scholar]
  78. Tirelli U., D'Incalci M., Canetta R., Tumolo S., Franchin G., Veronesi A., Galligioni E., Trovò M. G., Rossi C., Grigoletto E. Etoposide (VP-16-213) in malignant brain tumors: a phase II study. J Clin Oncol. 1984 May;2(5):432–437. doi: 10.1200/JCO.1984.2.5.432. [DOI] [PubMed] [Google Scholar]
  79. Walker M. D., Alexander E., Jr, Hunt W. E., MacCarty C. S., Mahaley M. S., Jr, Mealey J., Jr, Norrell H. A., Owens G., Ransohoff J., Wilson C. B. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978 Sep;49(3):333–343. doi: 10.3171/jns.1978.49.3.0333. [DOI] [PubMed] [Google Scholar]
  80. Walker M. D., Green S. B., Byar D. P., Alexander E., Jr, Batzdorf U., Brooks W. H., Hunt W. E., MacCarty C. S., Mahaley M. S., Jr, Mealey J., Jr Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980 Dec 4;303(23):1323–1329. doi: 10.1056/NEJM198012043032303. [DOI] [PubMed] [Google Scholar]
  81. Walker M. D., Hurwitz B. S. BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea; NSC-409962) in the treatment of malignant brain tumor--a preliminary report. Cancer Chemother Rep. 1970 Aug;54(4):263–271. [PubMed] [Google Scholar]
  82. Wilson C. B., Boldrey E. B., Enot K. J. 1,3-bis (2-chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of brain tumors. Cancer Chemother Rep. 1970 Aug;54(4):273–281. [PubMed] [Google Scholar]
  83. Yoneda T., Lyall R. M., Alsina M. M., Persons P. E., Spada A. P., Levitzki A., Zilberstein A., Mundy G. R. The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res. 1991 Aug 15;51(16):4430–4435. [PubMed] [Google Scholar]
  84. Yung W. K., Harris M. I., Bruner J. M., Feun L. G. Intravenous BCNU and AZQ in patients with recurrent malignant gliomas. J Neurooncol. 1989 Sep;7(3):237–240. doi: 10.1007/BF00172916. [DOI] [PubMed] [Google Scholar]
  85. Yung W. K., Mechtler L., Gleason M. J. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol. 1991 May;9(5):860–864. doi: 10.1200/JCO.1991.9.5.860. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES